Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations
- PMID: 12069170
- DOI: 10.1023/a:1015314314796
Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations
Abstract
Purpose: Highly lipophilic basic drugs, the antiestrogens AE 1 (log P = 5.82) and AE 2 (log P = 7.8) shall be delivered transdermally.
Methods: Transdermal permeation of drugs, enhancers, and solvents from various fluid formulations were characterized by in-vitro permeation studies through excised skin of hairless mice. Furthermore, differential scanning calorimetry (DSC) measurements of skin lipid phase transition temperatures were conducted.
Results: Transdermal flux of highly lipophilic drugs was extraordinarily enhanced by the unique permeation enhancer combination propylene glycol-lauric acid (9 + 1): steady-state fluxes of AE 1 and AE 2 were as high as 5.8 microg x cm(-2) x h(-1) and 3.2 microg x cm(-2) x h(-1), respectively. This dual enhancer formulation also resulted in a marked increase in the transdermal fluxes of the enhancers. Furthermore, skin lipid phase transition temperatures were significantly reduced by treatment with this formulation.
Conclusion: Transdermal delivery of highly lipophilic drugs can be realized by using the permeation enhancer combination propylene glycol-lauric acid. The extraordinary permeation enhancement for highly lipophilic drugs by this formulation is due to mutual permeation enhancement of these two enhancers and their synergistic lipid-fluidising activity in the stratum corneum.
Similar articles
-
In-vitro release and transdermal fluxes of a highly lipophilic drug and of enhancers from matrix TDS.J Control Release. 2002 Jul 18;82(1):63-70. doi: 10.1016/s0168-3659(02)00105-0. J Control Release. 2002. PMID: 12106977
-
Development of matrix patches for transdermal delivery of a highly lipophilic antiestrogen.Drug Dev Ind Pharm. 2003 Aug;29(7):785-93. doi: 10.1081/ddc-120021778. Drug Dev Ind Pharm. 2003. PMID: 12906336
-
Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement.Drug Deliv. 2002 Oct-Dec;9(4):239-47. doi: 10.1080/10717540260397855. Drug Deliv. 2002. PMID: 12511202
-
Amphiphilic transdermal permeation enhancers: structure-activity relationships.Curr Med Chem. 2005;12(19):2273-91. doi: 10.2174/0929867054864822. Curr Med Chem. 2005. PMID: 16178785 Review.
-
Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery.Curr Med Chem. 2000 Jun;7(6):593-608. doi: 10.2174/0929867003374840. Curr Med Chem. 2000. PMID: 10702628 Review.
Cited by
-
Investigating transdermal delivery of vitamin D3.AAPS PharmSciTech. 2015 Aug;16(4):963-72. doi: 10.1208/s12249-015-0291-3. Epub 2015 Jan 22. AAPS PharmSciTech. 2015. PMID: 25609377 Free PMC article.
-
Skin Delivery and Irritation Potential of Phenmetrazine as a Candidate Transdermal Formulation for Repurposed Indications.AAPS J. 2019 May 31;21(4):70. doi: 10.1208/s12248-019-0335-9. AAPS J. 2019. PMID: 31152318
-
Effect of Terpenes on the Enhancement of Skin Permeation of Lipophilic Drugs: A Systematic Review.Acta Med Philipp. 2024 Mar 15;58(4):59-71. doi: 10.47895/amp.vi0.6505. eCollection 2024. Acta Med Philipp. 2024. PMID: 38966611 Free PMC article.
-
Transdermal Drug Delivery of Tazarotene: Determining Tazarotene's Potential in Local Transdermal Therapy.Pharmaceutics. 2023 Dec 31;16(1):64. doi: 10.3390/pharmaceutics16010064. Pharmaceutics. 2023. PMID: 38258075 Free PMC article.
-
The Potential of Pharmaceutical Hydrogels in the Formulation of Topical Administration Hormone Drugs.Polymers (Basel). 2022 Aug 14;14(16):3307. doi: 10.3390/polym14163307. Polymers (Basel). 2022. PMID: 36015564 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources